美国镭学会食管癌患者使用食管支架的适当使用标准:系统评价和指南

IF 1.6 4区 医学 Q4 ONCOLOGY
Suzanne Russo, Christopher J Anker, D Chamil Codipilly, Gerard Abood, Dmitriy Akselrod, Christopher L Hallemeier, Krishan R Jethwa, Zhaohui Jin, Ed Kim, Timothy Kennedy, Percy Lee, Eric D Miller, Neil B Newman, J Eva Selfridge, Navesh Sharma, William Small, Leila Tchelebi, Vonetta M Williams, Charles B Simone
{"title":"美国镭学会食管癌患者使用食管支架的适当使用标准:系统评价和指南","authors":"Suzanne Russo, Christopher J Anker, D Chamil Codipilly, Gerard Abood, Dmitriy Akselrod, Christopher L Hallemeier, Krishan R Jethwa, Zhaohui Jin, Ed Kim, Timothy Kennedy, Percy Lee, Eric D Miller, Neil B Newman, J Eva Selfridge, Navesh Sharma, William Small, Leila Tchelebi, Vonetta M Williams, Charles B Simone","doi":"10.1097/COC.0000000000001222","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Esophageal cancer (EC) often presents with dysphagia due to tumor obstruction. Esophageal stenting has the potential of palliating dysphagia, improving nutrition, preventing aspiration, and improving quality of life (QoL) but may be associated with risks. The present systematic review and guidelines are intended to assist treatment decision-making when considering stent placement in patients with EC based on the available evidence.</p><p><strong>Methods: </strong>Using the population, intervention, comparator, outcome, timing and study design framework, the evidence was assessed using Cochrane and PRISMA 2020 methodology. Eligible studies included prospective phase II-III trials and retrospective analyses published between January 1, 2010 and December 3, 2024 in the Ovid Medline database. These references were assessed by American Radium Society (ARS) Appropriate Use Criteria (AUC) methodology. RAND-UCLA consensus methodology was used to rate the appropriateness of the use of stents.</p><p><strong>Results: </strong>ARS AUC recommendations include (1) esophageal stenting is usually not appropriate in patients with early-stage EC in whom upfront surgery is planned; (2) esophageal stenting is usually not appropriate in patients with locally-advanced EC in whom neoadjuvant/perioperative therapy and esophagectomy or definitive chemoradiation is planned; (3) esophageal stenting may be appropriate in the setting of metastatic EC, especially in patients with short life expectancy with limited treatment options; (4) esophageal stenting is usually not appropriate for benign stricture following curative-intent therapy; (5) esophageal stenting is usually not appropriate for locally recurrent tumor in the setting of prior radiation; and (6) esophageal stenting is usually appropriate for management of tracheoesophageal fistula before curative-intent treatment.</p><p><strong>Conclusions: </strong>This ARS AUC summary provides guidelines for the use of esophageal stents in patients with EC provides based on available evidence.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Executive Summary of the American Radium Society Appropriate Use Criteria for the Use of Esophageal Stents in Patients With Esophageal Cancer: Systematic Review and Guidelines.\",\"authors\":\"Suzanne Russo, Christopher J Anker, D Chamil Codipilly, Gerard Abood, Dmitriy Akselrod, Christopher L Hallemeier, Krishan R Jethwa, Zhaohui Jin, Ed Kim, Timothy Kennedy, Percy Lee, Eric D Miller, Neil B Newman, J Eva Selfridge, Navesh Sharma, William Small, Leila Tchelebi, Vonetta M Williams, Charles B Simone\",\"doi\":\"10.1097/COC.0000000000001222\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Esophageal cancer (EC) often presents with dysphagia due to tumor obstruction. Esophageal stenting has the potential of palliating dysphagia, improving nutrition, preventing aspiration, and improving quality of life (QoL) but may be associated with risks. The present systematic review and guidelines are intended to assist treatment decision-making when considering stent placement in patients with EC based on the available evidence.</p><p><strong>Methods: </strong>Using the population, intervention, comparator, outcome, timing and study design framework, the evidence was assessed using Cochrane and PRISMA 2020 methodology. Eligible studies included prospective phase II-III trials and retrospective analyses published between January 1, 2010 and December 3, 2024 in the Ovid Medline database. These references were assessed by American Radium Society (ARS) Appropriate Use Criteria (AUC) methodology. RAND-UCLA consensus methodology was used to rate the appropriateness of the use of stents.</p><p><strong>Results: </strong>ARS AUC recommendations include (1) esophageal stenting is usually not appropriate in patients with early-stage EC in whom upfront surgery is planned; (2) esophageal stenting is usually not appropriate in patients with locally-advanced EC in whom neoadjuvant/perioperative therapy and esophagectomy or definitive chemoradiation is planned; (3) esophageal stenting may be appropriate in the setting of metastatic EC, especially in patients with short life expectancy with limited treatment options; (4) esophageal stenting is usually not appropriate for benign stricture following curative-intent therapy; (5) esophageal stenting is usually not appropriate for locally recurrent tumor in the setting of prior radiation; and (6) esophageal stenting is usually appropriate for management of tracheoesophageal fistula before curative-intent treatment.</p><p><strong>Conclusions: </strong>This ARS AUC summary provides guidelines for the use of esophageal stents in patients with EC provides based on available evidence.</p>\",\"PeriodicalId\":50812,\"journal\":{\"name\":\"American Journal of Clinical Oncology-Cancer Clinical Trials\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-06-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Clinical Oncology-Cancer Clinical Trials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/COC.0000000000001222\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Clinical Oncology-Cancer Clinical Trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/COC.0000000000001222","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:食管癌(EC)常表现为肿瘤梗阻引起的吞咽困难。食管支架置入具有缓解吞咽困难、改善营养、防止误吸和提高生活质量(QoL)的潜力,但可能与风险相关。目前的系统评价和指南旨在根据现有证据帮助EC患者在考虑支架置入术时做出治疗决策。方法:采用人群、干预、比较物、结局、时间和研究设计框架,采用Cochrane和PRISMA 2020方法对证据进行评估。符合条件的研究包括2010年1月1日至2024年12月3日在Ovid Medline数据库中发表的前瞻性II-III期试验和回顾性分析。这些参考文献采用美国镭学会(ARS)适当使用标准(AUC)方法进行评估。采用RAND-UCLA共识方法评价支架使用的适宜性。结果:ARS AUC的建议包括:(1)对于计划进行前期手术的早期EC患者,食管支架植入术通常不合适;(2)食管支架植入术通常不适用于计划进行新辅助/围手术期治疗和食管切除术或最终放化疗的局部晚期EC患者;(3)食管支架植入术可能适用于转移性EC,特别是对于预期寿命短且治疗选择有限的患者;(4)食管支架植入术通常不适合治疗意图治疗的良性狭窄;(5)食管支架置入术通常不适用于局部复发肿瘤,且既往有放疗背景;(6)食管支架植入术通常适用于气管食管瘘治疗前的治疗。结论:ARS AUC总结基于现有证据为EC患者食管支架的使用提供了指南。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Executive Summary of the American Radium Society Appropriate Use Criteria for the Use of Esophageal Stents in Patients With Esophageal Cancer: Systematic Review and Guidelines.

Objectives: Esophageal cancer (EC) often presents with dysphagia due to tumor obstruction. Esophageal stenting has the potential of palliating dysphagia, improving nutrition, preventing aspiration, and improving quality of life (QoL) but may be associated with risks. The present systematic review and guidelines are intended to assist treatment decision-making when considering stent placement in patients with EC based on the available evidence.

Methods: Using the population, intervention, comparator, outcome, timing and study design framework, the evidence was assessed using Cochrane and PRISMA 2020 methodology. Eligible studies included prospective phase II-III trials and retrospective analyses published between January 1, 2010 and December 3, 2024 in the Ovid Medline database. These references were assessed by American Radium Society (ARS) Appropriate Use Criteria (AUC) methodology. RAND-UCLA consensus methodology was used to rate the appropriateness of the use of stents.

Results: ARS AUC recommendations include (1) esophageal stenting is usually not appropriate in patients with early-stage EC in whom upfront surgery is planned; (2) esophageal stenting is usually not appropriate in patients with locally-advanced EC in whom neoadjuvant/perioperative therapy and esophagectomy or definitive chemoradiation is planned; (3) esophageal stenting may be appropriate in the setting of metastatic EC, especially in patients with short life expectancy with limited treatment options; (4) esophageal stenting is usually not appropriate for benign stricture following curative-intent therapy; (5) esophageal stenting is usually not appropriate for locally recurrent tumor in the setting of prior radiation; and (6) esophageal stenting is usually appropriate for management of tracheoesophageal fistula before curative-intent treatment.

Conclusions: This ARS AUC summary provides guidelines for the use of esophageal stents in patients with EC provides based on available evidence.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.90
自引率
0.00%
发文量
130
审稿时长
4-8 weeks
期刊介绍: ​​​​​​​American Journal of Clinical Oncology is a multidisciplinary journal for cancer surgeons, radiation oncologists, medical oncologists, GYN oncologists, and pediatric oncologists. The emphasis of AJCO is on combined modality multidisciplinary loco-regional management of cancer. The journal also gives emphasis to translational research, outcome studies, and cost utility analyses, and includes opinion pieces and review articles. The editorial board includes a large number of distinguished surgeons, radiation oncologists, medical oncologists, GYN oncologists, pediatric oncologists, and others who are internationally recognized for expertise in their fields.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信